Cipla Given FDA Approval for Icatibant, Generic Version of Firazyr

Cipla Given FDA Approval for Icatibant, Generic Version of Firazyr
4
(1)

Cipla has received final approval from the U.S. Food and Drug Administration (FDA) for a generic version of Firazyr (icatibant injection), an approved treatment for acute attacks in adults with hereditary angioedema (HAE).

The company announced the FDA approval of its abbreviated new drug application for icatibant injectable in a press release. Cipla’s generic form of the medication will be available in a pre-filled 30 mg/3 mL syringe. It is designed to be administered under-the-skin (subcutaneously) in the abdominal area.

Firazyr was approved as a HAE treatment for acute attacks in adults (18 and older) by the FDA in 2011. The treatment was developed by Shire, which is now part of Takeda Pharmaceuticals.

The active ingredient in Firazyr is icatibant. Cipla’s new generic form has the same active ingredient. Like other generic medications, it was created to be equivalent to the reference product — in this case, Shire’s Firazyr — in terms of its effectiveness, safety, dosage, administration route, quality, and performance.

Icatibant works by blocking the activity of a protein called bradykinin. Bradykinin is a signaling molecule that, upon binding to its receptor, causes blood vessels to widen and grow more permeable. This allows fluid to leak out and build up in tissue — swelling.

Icatibant is a selective bradykinin B2 receptor antagonist, which means it blocks the receptor to which bradykinin usually binds — the bradykinin B2 receptor. By blocking this receptor, icatibant interrupts the bradykinin signaling that normally would lead to swelling.

In multiple Phase 3 clinical trials, icatibant has been demonstrated to be effective in the treatment of acute attacks in people with HAE. The medication also has been shown to have a good safety profile; the most common adverse events (side effects) reported in trials were injection site reactions, which were usually mild-to-moderate in intensity and went away with time.

In addition to Cipla’s newly approved version, other generic versions of Firazyr are available: one by Fresenius Kabi USA, one by Jiangsu Hansoh Pharmaceutical Group, and one by Teva Pharmaceuticals.

According to IQVIA, sales of icatibant products in the U.S. — including Firazyr and approved generic equivalents — totaled approximately $270 million for the 12-month period ending in May.

Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
Total Posts: 0
Patrícia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.
×
Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
Latest Posts
  • icatibant
  • Ruconest
  • berotralstat study
  • EMA, Ruconest

How useful was this post?

Click on a star to rate it!

Average rating 4 / 5. Vote count: 1

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Pin It on Pinterest

Share This